New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Can pollution cause it? What about inflammation? And how do tumors spread? Here’s what scientists are learning about this ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

The addition of high-dose IV vitamin C to standard chemotherapy nearly doubled OS for patients with advanced pancreatic ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

Today the American Cancer Society called out the need for more progress on pancreatic cancer, citing it as the third-leading ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study. Pancreatic cancer kills 50,000 people each year, according to ...

Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials ...